


BM-1244

Cat. No.:	HY-138832		
CAS No.:	1619923-32-8		
Molecular Formula:	C ₅₄ H ₅₉ ClF ₄ N ₆ O ₈ S ₄		
Molecular Weight:	1159.79		
Target:	Bcl-2 Family		
Pathway:	Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 200 mg/mL (172.45 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
		1 mM		0.8622 mL	4.3111 mL	8.6223 mL
5 mM			0.1724 mL	0.8622 mL	1.7245 mL	
	10 mM		0.0862 mL	0.4311 mL	0.8622 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 5 mg/mL (4.31 mM); Suspended solution; Need ultrasonic					

BIOLOGICAL ACTIVITY

Description	BM-1244 (APG-1252-M1) is a potent Bcl-xL/Bcl-2 inhibitor with K _i s of 134 and 450 nM for Bcl-xL and Bcl-2, respectively. BM-1244 inhibits senescent fibroblasts (SnCs) with an EC ₅₀ of 5 nM. (From patent WO2019033119A1) ^[1] .
--------------------	--

REFERENCES

- [1]. Jill Hopkins, et al. Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells. WO2019033119A1.
- [2]. Kim R. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun. 2005;333(2):336-343.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA